Quick Answer
Q32 Bio Inc. reported Operating Income Loss of $16.90 million for the year ending 2025.
- Q32 Bio Inc. showed an increase of +125.6% in Operating Income Loss from 2024 to 2025.
- This data is from Q32 Bio Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 9 years of available data (2017 to 2025), Q32 Bio Inc.'s Operating Income Loss has grown by 157.0%.
- Historical annual values: Fiscal year 2025: $16.90 million | Fiscal year 2024: -$66.10 million | Fiscal year 2023: -$48.26 million | Fiscal year 2022: -$133.28 million | Fiscal year 2021: -$95.95 million | Fiscal year 2020: -$130.26 million | Fiscal year 2019: -$109.94 million | Fiscal year 2018: -$59.93 million | Fiscal year 2017: -$29.66 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: